MCRB
Seres Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$84.84M
P/E Ratio
13.83
EPS
$0.64
Beta
0.26
52W High
$29.98
52W Low
$6.53
50-Day MA
$10.48
200-Day MA
$14.74
Dividend Yield
—
Profit Margin
722.00%
Forward P/E
10.26
PEG Ratio
-0.11
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 789,000 |
| Gross Profit (TTM) | $-54.81M |
| EBITDA | $-89.84M |
| Operating Margin | -4424.00% |
| Return on Equity | 19.60% |
| Return on Assets | -42.20% |
| Revenue/Share (TTM) | $0.09 |
| Book Value | $4.63 |
| Price-to-Book | 2.01 |
| Price-to-Sales (TTM) | 107.53 |
| EV/Revenue | 159.78 |
| EV/EBITDA | 12.83 |
| Quarterly Earnings Growth (YoY) | -91.90% |
| Quarterly Revenue Growth (YoY) | -93.40% |
| Shares Outstanding | $9.59M |
| Float | $7.28M |
| % Insiders | 11.83% |
| % Institutions | 25.63% |
Analyst Ratings
Consensus ($22.00 target)
1
Buy2
HoldData last updated: 4/8/2026